Clinical Trial Update: Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Chi-BEAC with auto-HSCT for aggressive lymphomas, reporting on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Double-hit Lymphoma
• Lymphoma
• Mantle Cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Chi-BEAC

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Lymphoma, Large B-Cell, Diffuse, Mantle Cell Lymphoma | Phase 2 | Status: UNKNOWN